NP

Nutra Pharma CorpOOTC NPHC Stock Report

Last reporting period 30 Sep, 2022

Updated 15 Nov, 2024

Last price

Market cap $B

0.001

Micro

Exchange

OOTC - OTC

NPHC Stock Analysis

NP

Uncovered

Nutra Pharma Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-20/100

Low score

Market cap $B

0.001

Dividend yield

Shares outstanding

7 596.85 B

Nutra Pharma Corp. operates as a bio pharmaceutical company. The company is headquartered in Coral Springs, Florida and currently employs 4 full-time employees. The company went IPO on 2001-10-09. The firm conducts drug discovery research and development activities on its own and through its subsidiary, ReceptoPharm, Inc. Its first consumer product, Cobroxin, is an over-the-counter pain reliever designed to treat moderate to severe chronic pain. Its second consumer product, Nyloxin, an over-the-counter pain reliever that is a stronger version of Cobroxin and is designed to treat severe chronic pain. Its Pet Pain-Away is an over-the-counter pain reliever designed to treat pain in cats and dogs. Its Equine Pain-Away is an over-the-counter topical pain reliever designed to treat pain in horses. Its Luxury Feet is an over-the-counter pain reliever and anti-inflammatory product, which is designed for women who experience pain or discomfort due to high heels and stilettos. The company also manufactures a zeolite detoxifier, Cell Defender for a third-party distributor.

View Section: Eyestock Rating